BCLSI
CNTA

Bain Capital Life Sciences Investors’s Centessa Pharmaceuticals CNTA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.2M Buy
+635,000
New +$16.2M 2.27% 12

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bain Capital Life Sciences Investors's CNTA Position: Q1 2026 in Review

Bain Capital Life Sciences Investors opened a new position in Centessa Pharmaceuticals (CNTA) in Q1 2026: 635,000 shares worth $25.2M. The stake represents 2.27% of the portfolio and ranks #12 among its holdings.

161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Bain Capital Life Sciences Investors held 635,000 shares of Centessa Pharmaceuticals worth $25.2M as of Q1 2026.
  • Centessa Pharmaceuticals was a new Bain Capital Life Sciences Investors position in Q1 2026.
  • Centessa Pharmaceuticals made up 2.27% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #12 holding.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.